Risankizumab safe, effective at 52 weeks for psoriatic arthritis
Risankizumab provides long-term benefits in patients with psoriatic arthritis (PsA) who have not achieved adequate response to previous therapies, according to a study recently published in Rheumatology.
Jan 11, 2023
0
5